

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)**

Meeting – December 10, 2014 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. November 12, 2014 DUR Minutes – Vote
B. November 12, 2014 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/SoonerPsych Program Update/Drug Rebate Program Review – See Appendix B

- A. Medication Coverage Activity for November 2014
B. Pharmacy Help Desk Activity for November 2014
C. Update on Medication Coverage Authorization Unit
D. SoonerPsych Program Update
E. Drug Rebate Program Review

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Harvoni[®] (Ledipasvir/Sofosbuvir) – See Appendix C

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Zubsolv[®] (Buprenorphine/Naloxone Tablets) and Bunavail[™] (Buprenorphine/Naloxone Buccal Films) – See Appendix D

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

7. Annual Review of Maintenance Asthma and Chronic Obstructive Pulmonary Disease Medications and 30-Day Notice to Prior Authorize Anoro[™] Ellipta[®] (Umeclidinium/Vilanterol), Incruse[™] Ellipta[®] (Umeclidinium), Spiriva[®] Respimat[®] (Tiotropium), and Striverdi[®] Respimat[®] (Olodaterol) – See Appendix E

- A. Current Prior Authorization Criteria
- B. Utilization of Maintenance Asthma and COPD Medications
- C. Prior Authorization of Maintenance Asthma and COPD Medications
- D. Market News and Updates
- E. Drug Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Maintenance Asthma and COPD Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

8. 30-Day Notice to Prior Authorize Ofev[®] (Nintedanib) and Esbriet[®] (Pirfenidone) – See Appendix F

- A. Introduction
- B. Drug Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Anderson, Dr. Muchmore, Chairman:

9. Annual Review of Testosterone Products and 30-Day Notice to Prior Authorize Natesto[™] (Testosterone Nasal Gel), Aveed[®] (Testosterone Undecanoate Injection), and Vogelxo[™] (Testosterone Topical Gel) – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization of Testosterone Products
- C. Prior Authorization of Testosterone Products
- D. Market News and Updates
- E. Drug Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Testosterone Products

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

10. Annual Review of Osteoporosis Medications and 30-Day Notice to Prior Authorize Duavee[®] (Conjugated Estrogens/Bazedoxifene) – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Osteoporosis Medications
- C. Prior Authorization of Osteoporosis Medications
- D. Market News and Updates
- E. Drug Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Osteoporosis Medications

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

11. FDA and DEA Updates – See Appendix I

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

12. Future Business

- A. Annual Reviews
- B. New Product Reviews

Items to be presented by Dr. Muchmore, Chairman:

13. Adjournment